Skip to main content

Manulife Global Fund – Healthcare Fund

Growth from long-term secular trends

Attractive opportunity capitalising on long-term secular trends

Learn more

Three guiding principles

Learn more

Fund information

Learn more


Attractive opportunity capitalising on long-term secular trends



Healthcare outperformed the broad equity market and most other sectors over the long term.


Total returns (31 Dec 1994 – 31 May 2024)1


Long-term secular trends

The global population is aging and there will be more demand for healthcare products and services, as well as increased investments in attaining medical breakthroughs. 



Ageing population2

Nearly 22% of the global population will be 60 years old and above by 2050. 


Rising healthcare spend3

The US spent 17% of its gross domestic product on healthcare in 2022, an increase of more than twofold over the last 20 years. 


Investments in medical advances4

The US Food & Drug Administration approved more than 400 novel drugs from 2015 to 2023, an average of 46 approvals a year. 


Resilience during economic downturns5

Healthcare also demonstrated resilience during economic downturns, due to the inelastic nature of demand for healthcare products and services.


Three guiding principles



The investment team is guided by these 3 principles in implementing the strategy and believes that healthcare companies with products and services that address these principles should potentially see unprecedented demand. 

The diligent and faithful implementation of these guiding principles has seen the Fund attain a consistent performance track record since inception. 


Cumulative growth of US$100 since inception (as of 31 May 2024)6


Fund information


  AA AA (SGD Hedged) Acc
Investment objective​ The Fund aims to provide medium to long term capital growth by investing mainly in equity and equity-related securities of companies in healthcare and related industries globally and which are listed on any stock exchange, which may include companies which derive a significant portion of their earnings from medical and pharmaceutical products and services. 
Inception date 27 Jun 2008
ISIN code LU0357321016 LU2468319806
Bloomberg ticker MGFHEAL LX MLHCAAS LX
Base currency​ USD
Mode of subscription Cash Cash and SRS
Minimum investment USD 1,000 (or the equivalent in any other major currency)
Distribution frequency​​ N.A.
Management fee 1.50% p.a.
Initial sales charge Up to 5.0%
Dealing frequency Daily
Investment manager Manulife Investment Management (US) LLC
Fund size USD 405.2 million (as of 31 May 2024)

Portfolio manager


Steven G. Slaughter

Steve is a member of the capital appreciation team and lead portfolio manager of the global healthcare strategy. He also conducts fundamental research on the healthcare sector for all large-cap equity and thematic-based strategies managed by the team.

Prior to joining the firm, he was a portfolio manager at Oak Ridge Investments and, before that, he was a portfolio manager and senior investment analyst at UBS Global Asset Management, where he directed healthcare investments for U.S. core and global portfolios.

Steve has a background in private equity and has held various corporate management roles within the healthcare industry, including Johnson & Johnson, Abbott Labs, and Elan Pharmaceuticals. 



1. Source: Bloomberg, as of 31 May 2024. Rebased at 100 as of Dec 1994. Past performance is not indicative of future results. It is not possible to directly invest in an index.




5. Source: Morningstar, as of 31 May 2024. Past performance is not indicative of future results.

6. Cumulative return is 206.8% on offer-to-bid basis. Since inception (27 June 2008), the class returned 7.64% (annualised) on NAV-to-NAV basis and 7.30% (annualised) on offer-to-bid basis. Performance figures are calculated with all dividends and distributions reinvested, taking into account all charges which would have been payable upon such reinvestment. Past performance is not indicative of future results.


Important Information

Manulife Global Fund (the “Company”) is an open-ended investment company registered in the Grand Duchy of Luxembourg. The Manulife Global Fund – Healthcare Fund (the "Fund") is recognised under the Securities and Futures Act of Singapore for retail distribution. The Company has appointed Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration Number: 200709952G) as its Singapore Representative and agent for service of process in Singapore. The information provided herein does not constitute financial advice, an offer or recommendation with respect to the Fund. Opinions, forecasts and estimates on the economy, financial markets or economic trends of the markets mentioned herein are not necessarily indicative of the future or likely performance of the Fund. The Fund may use financial derivative instruments for the purposes of investment, efficient portfolio management and/or hedging.  

Investments in the Fund are not deposits in, guaranteed or insured by the Manager and involve risks. Past performance of the manager or sub-manager is not necessarily indicative of its future performance. The value of units in the Fund and any income accruing to them may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. Investors should read the Singapore prospectus, and seek advice from a financial adviser before deciding whether to purchase units in the Fund. A copy of the Singapore prospectus and the product highlights sheet can be obtained from Manulife or its distributors. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund is suitable for him. 

Distributions are not guaranteed. Investors should refer to the Singapore prospectus for the distribution policy of the Fund. The Directors of the Company shall have the absolute discretion to determine whether a distribution is to be made in respect of the Fund as well as the rate and frequency of distributions to be made. Distributions may be made out of (a) income, or (b) net realized gains, or (c) capital of the Fund, or (d) gross income while charging all or part of the fees and expenses to capital, or (e) any combination of (a), (b), (c) and/or (d). Past distribution yields and payments are not necessarily indicative of future distribution yields and payments. Any payment of distributions by the Fund is expected to result in an immediate decrease in the net asset value per share of the Fund. 

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.